Please use this identifier to cite or link to this item:
Title: Hesperetin, a Citrus bioflavonoid, prevents IL-1β-induced inflammation and cell proliferation in lung epithelial A549 cells
Authors: Ramteke, Prerna
Yadav, Umesh C. S.
Keywords: Anticancer;Anti-inflammatory;Antioxidant;COX-2;Lung cancer
Issue Date: Jan-2019
Publisher: NISCAIR-CSIR, India
Abstract: Hesperetin, a Citrus bioflavonoid, exhibits anticancer, anti-inflammatory and antioxidant properties. However, its action and mechanism in inflammation-induced lung cancer is unknown. We have investigated anticancer effects of hesperetin in IL-1β-stimulated lung adenocarcinoma cell proliferation and COX-2 -mediated inflammation. The human lung adenocarcinoma A549 cells were serum-starved with or without HN (100 μM) for overnight and stimulated with IL-1β for varying durations. Cell viability and proliferation were assessed by MTT and wound healing assays. Cell cycle progression was measured by flow cytometry, and RT-PCR and immunoblotting methods were used to examine the expression COX-2 mRNA and protein, respectively. Protein stability assessed by cycloheximide chase assay. IL-1β caused a time- and dose-dependent increase in cell viability and proliferation, expression of COX-2 at transcription as well as translation levels, increased the stability of COX-2 protein, and PGE2 production while  HN significantly decreased these changes. Further, IL-1β stimulated increased phosphorylation of ERK-1/2 and p65 subunit of NF-κB, which were reversed by HN in A549 cells. These results show that HN could inhibit IL-1β-stimulated cell proliferation, COX-2 expression and its regulation at translation level and PGE2 synthesis in A549 lung epithelial cells, indicating its anti-inflammatory and anticancer potential in lung cancer cells.
Page(s): 7-14
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.57(01) [January 2019]

Files in This Item:
File Description SizeFormat 
IJEB 57(1) 7-14.pdf624.6 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.